174 related articles for article (PubMed ID: 34178653)
1. The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620.
Zha JH; Xia YC; Ye CL; Hu Z; Zhang Q; Xiao H; Yu BT; Xu WH; Xu GQ
Front Oncol; 2021; 11():669518. PubMed ID: 34178653
[TBL] [Abstract][Full Text] [Related]
2. GDC-0349 inhibits non-small cell lung cancer cell growth.
Yang H; Zhao J; Zhao M; Zhao L; Zhou LN; Duan Y; Li G
Cell Death Dis; 2020 Nov; 11(11):951. PubMed ID: 33154352
[TBL] [Abstract][Full Text] [Related]
3. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
4. GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms.
Jin L; Zhang W; Yao MY; Tian Y; Xue BX; Tao W
Cell Death Discov; 2022 Mar; 8(1):120. PubMed ID: 35296639
[TBL] [Abstract][Full Text] [Related]
5. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V.
Sun X; Shan HJ; Yin G; Zhang XY; Huang YM; Li HJ
Cell Death Discov; 2022 Feb; 8(1):48. PubMed ID: 35115496
[TBL] [Abstract][Full Text] [Related]
6. An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth.
Chen F; Zhao H; Li C; Li P; Zhang Q
Cell Death Discov; 2022 Jun; 8(1):293. PubMed ID: 35717530
[TBL] [Abstract][Full Text] [Related]
7. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
Xu X; Jiang J; Yao L; Ji B
Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
10. Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth.
Jin L; Zhu J; Yao L; Shen G; Xue BX; Tao W
Cell Death Dis; 2023 Aug; 14(8):537. PubMed ID: 37604912
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
12. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
13. Preclinical study of CC223 as a potential anti-ovarian cancer agent.
Jin Z; Niu H; Wang X; Zhang L; Wang Q; Yang A
Oncotarget; 2017 Aug; 8(35):58469-58479. PubMed ID: 28938571
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Rageot D; Bohnacker T; Melone A; Langlois JB; Borsari C; Hillmann P; Sele AM; Beaufils F; Zvelebil M; Hebeisen P; Löscher W; Burke J; Fabbro D; Wymann MP
J Med Chem; 2018 Nov; 61(22):10084-10105. PubMed ID: 30359003
[TBL] [Abstract][Full Text] [Related]
15. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
16. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
[TBL] [Abstract][Full Text] [Related]
17. The sphingosine kinase inhibitor SKI-V suppresses cervical cancer cell growth.
Zhang Y; Cheng L; Shi X; Song Y; Chen XY; Chen MB; Yao J; Zhang ZQ; Cai S
Int J Biol Sci; 2022; 18(7):2994-3005. PubMed ID: 35541904
[TBL] [Abstract][Full Text] [Related]
18. The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
Tarantelli C; Gaudio E; Hillmann P; Spriano F; Sartori G; Aresu L; Cascione L; Rageot D; Kwee I; Beaufils F; Zucca E; Stathis A; Wymann MP; Cmiljanovic V; Fabbro D; Bertoni F
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167506
[TBL] [Abstract][Full Text] [Related]
19. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
[TBL] [Abstract][Full Text] [Related]
20. GDC-0084 inhibits cutaneous squamous cell carcinoma cell growth.
Ding LT; Zhao P; Yang ML; Lv GZ; Zhao TL
Biochem Biophys Res Commun; 2018 Sep; 503(3):1941-1948. PubMed ID: 30072096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]